Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Rental Rate Antitrust Lawsuit
    • Automobile 3G Network Shutdown Lawsuit
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
7.23.2019

Antidepressants, Bladder Drugs Tied to Nearly 50% Higher Dementia Risk

By Brian Lynch
In The News, You Should Know

For anyone who has experienced it firsthand, dementia is one of the most difficult and heartbreaking medical conditions. The loss of a lifetime’s worth of memories and the inability to continue with daily activities can place an unbearable burden on families and loved ones. There is no cure for dementia, and medical science hasn’t found a way to completely predict who and when it will strike. But we may be slightly closer to minimizing risk factors, as a new study published in the journal JAMA Internal Medicine suggests that certain classes of antidepressants, bladder, and antiepileptic drugs are potentially tied to a nearly 50% higher dementia risk.

The drugs in question are known as anticholinergics, a class of medication that inhibits involuntary muscle movements and various bodily functions by blocking the actions of acetylcholine neurotransmitters. Anticholinergics are used to treat a variety of medical conditions, including depression, overactive bladder, asthma, and symptoms of Parkinson’s disease.

The study was conducted in the United Kingdom at the University of Nottingham. Researchers utilized a database of anonymized data on over 284,000 adults aged 55 and older between 2004 and 2016 provided by the group QResearch. Researchers analyzed each adult’s exposure to anticholinergics based on their prescription details.

Researchers discovered that there were nearly 50% increased odds of developing dementia in patients with a total anticholinergic exposure of more than 1,095 daily doses within a 10-year period – the equivalent to an older adult taking strong anticholinergic drugs daily for at least three years.

Specific anticholinergic drugs that specifically showed increased risks of dementia include anticholinergic antidepressants, antipsychotics, antiparkinsons, bladder, and epilepsy drugs. The most frequently prescribed of these drugs were antidepressants, anti-vertigo, and bladder antimuscarinic drugs used to treat overactive bladders. Other anticholinergic drugs such as antihistamines and gastrointestinal drugs showed no increased risks of dementia.

While this information is certainly troubling, it’s important to note the limitations of the study. Since researchers utilized existing patient data rather than directly monitoring patients, it’s possible that patients did not take prescribed medication as directed, and anticholinergic exposure levels could have been misclassified. Researchers also stress that their findings point to only an association between the drugs and dementia risk, not a causal relationship.

“However, if this association is causal, the population-attributable fractions indicate that around 10% of dementia diagnoses are attributable to anticholinergic drug exposure, which would equate, for example, to around 20,000 of the 209,600 new cases of dementia per year in the United Kingdom,” the researchers wrote in the study.

The study’s researchers stated that more research is needed to clarify whether anticholinergic medications truly represent a reversable risk factor for dementia.

If you have been harmed by a dangerous drug or medical device, we are here to help. Contact Wexler Wallace and speak to one of our attorneys about your potential claim.

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • The Firm
    • Around The World
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2023 © Wexler Boley & Elgersma LLP

Wexler Boley & Elgersma uses cookies to improve the performance and functionality of this site. By using our website, you are providing us with your consent to use cookies on this site. Close Privacy Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT